Thoracic Oncology
Bio-Thera Solutions Ltd. focuses its clinical research on stage IV non-squamous non-small cell lung cancer, with interest in first-line treatment settings for advanced lung cancer.
- Non-squamous non-small cell lung cancer
- Advanced metastatic disease
- First-line systemic therapy
The sponsor’s oncology work is centered on treatment options relevant to patients with advanced NSCLC requiring combination therapy.
Immuno-Oncology
The clinical programme includes interest in Keytruda-referenced comparators and immune checkpoint inhibition, reflecting a focus on immunotherapy-based management of non-small cell lung cancer.
- Immune checkpoint therapy
- Anti-PD-1 treatment
- Oncology biologics
Research activity in this area is directed toward therapeutic equivalence assessment within an immunotherapy framework.
Comparative Pharmacokinetics
The sponsor is active in pharmacokinetic comparison work involving BAT3306 and reference pembrolizumab products, with attention to exposure similarity across regional formulations.
- PK similarity assessment
- Reference biologic comparison
- Bioanalytical oncology studies
This area supports evaluation of how closely the investigational biologic aligns with established anti-cancer immunotherapy products.
Combination Cancer Therapy
Clinical interest extends to the use of BAT3306 alongside chemotherapy, with efficacy assessment based on tumour response outcomes in advanced lung malignancy.
- Chemo-immunotherapy combinations
- Objective response rate
- Solid tumour treatment
The therapeutic emphasis is on integrated regimens for patients with metastatic thoracic cancer.
Biologic Development for Oncology
Bio-Thera Solutions Ltd., through its Clinical Operation Department in Guangzhou, is involved in oncology biologic development with activity concentrated in a single active study site network in China.
- Therapeutic biologics
- Oncology clinical operations
- Comparative efficacy evaluation
The research portfolio currently centers on a focused lung cancer programme.
